PDCD1 and colorectal carcinoma: Even if in esophageal, gastric, and NSCLC the PD-L1 expression could be a valuable predictor of response to anti-PD-1 therapy [79,80], it was not formally demonstrated to be associated with survival or response to immunotherapy in CRC [81,82].